• Chahine, K. G. (2010). Anchoring gene patent eligibility to its constitutional mooring. Nature Biotechnology, 28(12), 1251–1255.

• Chahine, K. G. (2010). Patent decisions pending. Burrill Biotech.

• Chahine, K. G. (2010). Amicus Brief in American Civil Liberties Union v. Myriad Genetics. S.D.N.Y.

• Chahine, K. G. (2009). Utah must capitalize on its unique database. Salt Lake Tribune.

• Chahine, K. G. (1998). The importance of “legalese” in biotechnology patents. Nature Biotechnology, 16, 971–972.

• Chahine, K. G. (1998). Building the proper foundation for genomic-based patents. Nature Biotechnology, 16, 683–684.

• Chahine, K. G. (1997). Enabling DNA and protein claims: Why claiming biological equivalents encourages innovation. American Intellectual Property Law Association Quarterly Journal, 25(3), 333.

• Chahine, K. G. (1997). Patenting genes: Just when you thought it was safe. Nature Biotechnology, 15, 586–587.

• Chahine, K. G. (1997). Going beyond the native: Protecting DNA and protein patents. Nature Biotechnology, 15, 183–185.

• Gilmour, B. P., Goldman, D., Chahine, K. G., & Garner, P. D. (1995). Electrical activity suppresses nicotinic acetylcholine receptor gamma subunit promoter activity. Developmental Biology, 168, 416–428.

• Walke, W., Staple, J., Adams, L., Gnegy, M., Chahine, K., & Goldman, D. (1994). Calcium-dependent regulation of rat and chick muscle nicotinic acetylcholine receptor (nAChR) gene expression. Journal of Biological Chemistry, 269(30), 19447–19456.

• Chahine, K. G., & Goldman, D. (1994). Calcium regulates the expression of the nicotinic acetylcholine receptor subunit RNAs. Journal of Biological Chemistry, 269, 19447–19456.

• Chahine, K. G., Staple, J., Vanover, L., Barachini, E., & Goldman, D. (1993). Coupling muscle electrical activity to nicotinic acetylcholine receptor gene expression via a cyclic AMP-dependent second messenger system. Journal of Biological Chemistry, 268, 2893–2898.

• Chahine, K. G., Staple, J., & Goldman, D. (1992). Cyclic AMP and calcium regulate the expression of the nicotinic acetylcholine receptor. Society for Neuroscience Abstracts, 18, 540.4.

• Chahine, K. G., Walke, W., & Goldman, D. (1992). A 102 base pair sequence confers electrical regulation on the nicotinic acetylcholine receptor (nAChR) delta-subunit. Development, 12, 123–128.

• Angelotti, T. P., Tan, F., Chahine, K. G., & Macdonald, R. (1992). Molecular and electrophysiological characterization of the allelic variant of the rat alpha-6 GABA-A receptor subunit. Molecular Brain Research, 16, 173–178.

• Chahine, K. G., Staple, J., Vanover, L., Barachini, E., Walke, W., & Goldman, D. (1991). Muscle activity suppresses the expression of embryonic-type nicotinic acetylcholine receptor (nAChR) genes via a cyclic AMP second messenger system. Society for Neuroscience Abstracts, 17, 610.9.

• Chahine, Intellectual Property Owners Association, Webinar: Whole-genome sequencing v. gene patents: the coming showdown, November 3, 2010.

• Chahine, Intellectual Property Owners Association, Webinar: Gene Patents: What to Do After Myriad, May 25, 2010.

• Chahine, PBS NewsHour with Jim Lehrer, Courts Invalidate Patents on Cancer Genes, April 2, 2010.

• Chahine, KPCC (LA and Orange County) public radio: Gene Patenting, April 2, 2010.

• Chahine, Burrill Report Podcast: Why Biotech Is Worried About The Fight Over Gene Patents, February 22, 2009.

• Chahine, Burrill Report Podcast: An analysis of the Bilski Oral Arguments, October 26, 2009.

• Chahine, Industry opposes genomic legislation. Nature Biotechnology, 20, 419 (2002).

• Chahine, Amgen preserves erythropoietin monopoly. Nature Biotechnology, 19, 188 (2001).

• Chahine, Hatch-Waxman changes debated. Nature Biotechnology, 18, 710–711 (2000).

• Chahine, Amgen battles for EPO in Congress. Nature Biotechnology, 16, 999–1000 (1998).

• Chahine, Patent office resurrects EST debate. Nature Biotechnology, 16, 711 (1998).

• Chahine, Genentech sues to protect clot buster. Nature Biotechnology, 16, 410 (1998).

• Chahine, US courts disagree on generic exclusivity. Nature Biotechnology, 16, 132 (1998).

• Brower, V., Chahine, K., Dorey, E., Dove, A., Francisco, M., Hodgson, J., Michael, A., & Marshall, A. (1998). Cancer prognostic approved. Nature Biotechnology, 16, 121.

• Chahine, Elanex battles for piece of erythropoietin market. Nature Biotechnology, 16, 16 (1998).

• Chahine, Wrangling over the rights to BRAC1. Nature Biotechnology, 15, 936 (1997).

• Chahine, An Industry in Focus: Utah’s Biotechnology Boom. Utah Business, Oct, 27–31 (1997).

• Chahine & Giddings, B. (1997). University of Colorado wins inventorship dispute with American Cyanamid. Nature Biotechnology, 15, 831.

• Chahine, Eli Lilly Wins on Appeal. Nature Biotechnology, 15, 823 (1997).

• Chahine, Amgen Protects its Billion Dollar Protein. Nature Biotechnology, 15, 496–497 (1997).

• US-12334191-B2 Haplotype Phasing Models

• US-12062452-B2 Predicting Health Outcomes

• US-20240209453-A1 Liver Cancer Methylation And Protein Markers And Their Uses

• US-11335435-B2 Identifying Ancestral Relationships Using A Continuous Stream Of Input

• US-20210082578-A1 Predicting Health Outcomes

• US-10867705-B2 Predicting Health Outcomes

• US-20200303035-A1 Haplotype Phasing Models

• US-20200286591-A1 Reducing Error In Predicted Genetic Relationships

• US-10720229-B2 Reducing Error In Predicted Genetic

• US-10679729-B2 Haplotype Phasing Models

• US-20190267109-A1 Family Networks

• US-10296710-B2 Family Networks

• US-20190139624-A1 Identifying Ancestral Relationships Using A Continuous Stream Of Input

• US-10114922-B2 Identifying Ancestral Relationships Using A Continuous Stream Of Input

• US-20180301227-A1 Predicting Health Outcomes

• US-20170262577-A1 Haplotype Phasing Models

• US-9732376-B2 Sample Collection Device

• US-20170220738-A1 Reducing Error In Predicted Genetic

• US-20160300012-A1 Family Networks

• US-9390225-B2 Family Networks

• US-20160026755-A1 Identifying Ancestral Relationships Using A Continuous Stream Of Input

• US-20150056716-A1 Sample Collection Device

• US-20140278138-A1 Family Networks

Ken has been invited to speak before Presidential Committees, national think tanks, and leading academic institutions on the legal, scientific, and ethical implications of emerging health technologies. His expertise in gene patentability, genomic privacy, and regulatory policy has positioned him as a trusted voice in shaping national dialogue. In addition to academic and policy settings, Ken has presented at major investor and banking conferences, offering insights into biotechnology innovation, risk, and opportunity.